ArticleInternational journal of nanomedicine2025
CoFe
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of a Hypoxia-Triggered Supramolecular Nanoplatform for Synergistic Hypoxia Alleviation and Amplified Photodynamic Cancer Therapy.Molecules (Basel, Switzerland) · 2026Article
- Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Developing nanodrugs with passive targeting capabilities that can effectively overcome the oxidative-redox homeostasis-inhibiting microenvironment of tumors offers new insights into the precise treatment of osteosarcoma. Methods: CoFe Results: CF@P has a size of approximately 100 nm and can stably exist under physiological conditions. It exhibits excellent photothermal effects under near-infrared II (1064 nm) laser irradiation, synergistically enhancing its catalytic activity. CF@P alleviates hypoxia by decomposing endogenous H Conclusion: The CF@P nanozyme integrates the properties of multi-enzyme catalysis and photothermal therapy, disrupting the oxidative-redox homeostasis of tumor tissues, generating highly toxic hydroxyl radicals, and efficiently inducing apoptosis in osteosarcoma cells. This approach provides a new, efficient, and safe strategy for the precise treatment of hypoxic solid tumors like osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.